Introduction {#sec1-1}
============

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, idiosyncratic, multi-system reaction characterized by the clinical triad of fever, rash, and internal organ involvement. The mortality rate is estimated to be 8%, especially among patients with liver involvement, so early recognition is imperative. Drugs commonly associated with the development of DRESS syndrome include anticonvulsants, long-acting sulfonamides, and anti-inflammatory medications; however, there are no reported cases implicating anti-tuberculosis (anti-TB) medications. We report a case of DRESS syndrome from anti-TB therapy.

Case Report {#sec1-2}
===========

A 68-year-old Filipino man with history of diabetes and newly diagnosed pulmonary tuberculosis (TB) on rifampin, INH, ethambutol, and pyrazinamide presented to clinic with diffuse skin eruption for past 7-10 days. The patient initially developed a pruritic rash that began on his neck and eventually covered most of his body. The patient reports soreness with swallowing that started 7 days ago but denies any regurgitation. Exam was significant for diffuse, confluent, blanching, erythematous macular rash on face, scalp, upper extremities, including palms and soles, abdomen, buttocks, upper and lower extremities, no bullae formation, and no excoriation. There were moist mucous membranes, lips slightly edematous, dry, cracking, no blistering, and good dentition without abscesses. There was no conjunctival involvement \[[Figure 1](#F1){ref-type="fig"}\]. The patient was directly admitted form clinic to University Hospital. The patient was seen by both Dermatology and Allergy/Immunology service. All four TB medications were immediately discontinued because of possible suspicion of allergic reaction. Intravenous hydration was started with normal saline at 100 ml/h with electrolytes supplementation. On admission, the laboratory findings were significant for eosinophilia and transaminitis. The patient was started on steroid cream to face twice a day as per recommendations from Dermatology for erythema multiforme. Next day of admission, the patient had worsen eosinophilia and transaminitis. Punch biopsy skin was found to be erythema multiforme. During the hospital course, the patient had desquamation of skin so he was started on steroids and later was discharged on day 10 on TB therapy and 3-week tapering dose of prednisone as well as second-line TB therapy cycloserine and moxifloxacin, as an outpatient recommended by the Pulmonary team. After 2 weeks of follow up as outpatient, there was regression in rashes of the patient and after 1 month the rashes disappeared. The eosinophils normalized on repeat labs \[[Figure 2](#F2){ref-type="fig"}\].
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Discussion {#sec1-3}
==========

To our knowledge, this is the first reported case of DRESS syndrome caused by anti-TB medications. A systemic allergic reaction to anticonvulsant therapy was first described in 1950 and was named anticonvulsant hypersensitivity syndrome when associated with phenytoin therapy.\[[@ref1]\] Since then it has been known as drug hypersensitivity syndrome and is now more often referred to as DRESS syndrome, when it involves a case of "drug rash with eosinophilia and systemic symptoms."\[[@ref1][@ref2]\] DRESS syndrome is a specific, severe, idiosyncratic drug reaction characterized by a skin rash with fever, facial edema, lymphadenopathy, and visceral involvement (hepatitis, pneumonitis, myocarditis, nephritis, and colitis). The diagnosis can be difficult because many of the clinical features can be nonspecific, and the syndrome often mimics infectious, neoplastic, or rheumatologic conditions.

The diagnosis of DRESS syndrome involves three criteria as follows.

1\) Drug-induced skin eruption. 2) Eosinophilia ≥1.5 × 10^9^/L or atypical lymphocytes. 3) At least one of the following systemic abnormalities: Enlarged lymph nodes at least 2 cm in diameter, hepatitis, interstitial nephropathy, interstitial lung disease, or myocardial involvement. The pathogenesis is likely to be a drug-induced hypersensitivity caused by abnormalities in the production and detoxification of its active metabolites. A genetic predisposition may also exist, as evidenced by an increased risk in patients with a family history of DRESS syndrome. The syndrome may be related to epoxide hydrolase deficiency, which leads to accumulation of toxic metabolites, known as arene oxides that may trigger an immunologic response. An association between human herpesvirus 6 infection and the development of DRESS syndrome has been suggested in susceptible patients.\[[@ref3][@ref4][@ref5]\] DRESS syndrome can be life threatening and it has a documented mortality rate of about 10%,\[[@ref6]\] especially in patients who have liver involvement. All kinds of drugs can be involved. The syndrome is most frequently seen in association with anticonvulsants and antibiotic agents. An overview is shown in [Table 1](#T1){ref-type="table"}.
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Other diagnoses for skin abnormalities after drug use include Stevens-Johnson Syndrome (SJS)/Toxic Epiderma Necrolysis (TEN), pustular drug eruptions, and erythematous drug eruptions in general. The causative drugs for SJS/TEN are for the greater part similar to those of DRESS syndrome. Also, carbamazepine-induced fulminant hepatic failure in the setting of DRESS syndrome has been described.\[[@ref4][@ref5]\] Cases of DRESS syndrome associated with colitis have also been described.\[[@ref17]\] To our knowledge, this is the first report of concomitant subfulminant hepatitis and colitis in the patient. Early withdrawal of the offending medication is the first best step. The recovery from this condition has been reported to be slow, lasting several weeks to months; recurrences have also been reported.\[[@ref14]\] Glucocorticoids remain the most widely used agents for treatment of DRESS syndrome and can result in clinical improvement although well-controlled clinical trials are lacking. No randomized controlled trials of corticosteroids in the treatment of DRESS syndrome are available. Relapse can occur during the tapering of glucocorticoids.\[[@ref15]\] Successful use of IV immune globulin in nevirapine-induced DRESS syndrome has been reported.\[[@ref3]\] In our patient, use of glucocorticoid helped to prevent progression of disease. Avoiding re-exposure is recommended and first-degree relatives of an afflicted individual have a four-fold increased risk of drug sensitivity; therefore, family counseling is recommended.

Conclusion {#sec1-4}
==========

DRESS syndrome is always considered when there is high eosinophil count and multisystem involvement with skin eruptions. It can be a potentially life-threatening condition with certain drugs and infectious agents in predisposed individuals. It is imperative to discontinue the causative medication and avoid re-exposure.\[[@ref20]\]
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